Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 30+ AI models, with 0% extra fees
US FDA reverses course, will review Moderna's revised flu vaccine application
US FDA reverses course, will review Moderna’s revised flu vaccine application
Reuters
Wed, February 18, 2026 at 11:47 PM GMT+9 2 min read
In this article:
MRNA
+8.41%
Feb 18 (Reuters) - Moderna said on Wednesday the U.S. drug regulator will review its modified flu vaccine application, a week after rejecting the original submission and fueling industry concerns over shifts in the agency’s decision-making under the current administration.
Shares of the vaccine maker rose more than 6% in early trading on the news.
The company said the U.S. Food and Drug Administration has accepted its revised application seeking full approval for the shot for adults aged between 50 and 64, and accelerated approval for those aged 65 and above.
Moderna has also agreed to conduct a post-marketing study in older adults.
The regulator’s initial refusal had amplified concerns about a sharp shift in U.S. vaccine policy under the Trump administration, which has contributed to falling vaccination rates and reshaped the regulatory landscape for new shots.
U.S. Health Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic and a prominent critic of the mRNA technology, used in Moderna’s and most other COVID‑19 vaccines, recently oversaw the cancellation of a $600 million government contract to develop mRNA shots for bird flu and other high‑risk strains.
Citi analyst Geoff Meacham said the “about-face” by the FDA on Moderna’s experimental shot review “potentially brings back a revenue stream which had been in limbo”.
The regulator had rejected Moderna’s application, saying the company should have given a higher-strength vaccine to older patients in the control arm of its trial.
FDA Commissioner Dr. Marty Makary said on Tuesday that the agency had advised the company to give people aged 65 and older in its control group, the standard of care, which according to the Centers for Disease Control and Prevention’s recommendation should be a high-dose flu vaccine for people in that group.
The HHS, which oversees the FDA, was not immediately available for comment.
“Such a public airing of a dispute between a sponsor and the Agency is uncommon, but the quick reversal of FDA’s initial position should be a tailwind for bulls who argue Moderna can effectively leverage public pressure against” mRNA skeptics at the FDA, Leerink Partners analyst Mani Faroohar said.
The regulator is expected to make a decision on the candidate by August 5.
“Pending FDA approval, we look forward to making our flu vaccine available later this year so that America’s seniors have access to a new option to protect themselves against flu,” Moderna CEO Stéphane Bancel said.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli)
Terms and Privacy Policy
Privacy Dashboard
More Info